JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response - Wikidata - awgldk - TriplyDB

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

http://www.wikidata.org/entity/Q35163764

about

Recent advances in understanding myelofibrosis and essential thrombocythemia Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib The Hematopoietic Niche in Myeloproliferative Neoplasms Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest A hostel for the hostile: the bone marrow niche in hematologic neoplasms The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.Lysyl oxidase is associated with increased thrombosis and platelet reactivity.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis.Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.Turning the tide in myelodysplastic/myeloproliferative neoplasms.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Stem and progenitor cell alterations in myelodysplastic syndromes.Kinase signaling and targeted therapy for primary myelofibrosis.Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells.Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.Microchip-based single-cell functional proteomics for biomedical applications.Highly Multiplexed Single-Cell In Situ Protein Analysis with Cleavable Fluorescent Antibodies.Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment.Current Advances in Highly Multiplexed Antibody-Based Single-Cell Proteomic Measurements.Gain of function in Jak2V617F-positive T-cells.Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies.Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response.Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments.

P2860

Q26748543-B2D2172A-75BF-4CFB-931B-CFD26F7DC725 Q26750696-CDEFC715-1EBF-4513-AFA1-D23D2DB75692 Q26773192-0C164F9D-C52E-47C6-8745-FAC808896EA9 Q26777398-2A23FB67-6960-4984-AE01-F1C9C7353E7A Q26777629-F9F2A385-5455-45B9-8E19-F5262D9601A0 Q26779929-3B105E67-042F-40E6-82D9-600314E6BD2D Q26779936-8C8B18DF-89D2-41DA-A5FD-EFC2A921DCED Q26779960-C0B8FAC3-34DC-441D-A9FF-BD851C5EF54F Q28395194-62B8C7E4-DECB-446B-863C-E610981BFE0C Q33431469-D9B60E74-FED4-46D2-B6AD-D5168A8B545F Q33438420-FC7AB441-22D0-4375-B0EB-BD53B8CDA798 Q33443580-0F117DA5-618F-435E-A776-A4EA0DAF59A4 Q33709629-4587E5DD-6D87-4432-B591-1A8F513A6083 Q35627994-00166413-DF52-41DE-AD67-05EB6B6CD068 Q35841839-D24FE86D-C42A-449C-AB3A-3BBD26EE215F Q36322765-77AF403F-C1A0-44D4-A87F-3072F871BAF0 Q36700494-68C1F512-2494-49C7-A593-CEA22740CEE5 Q36782943-8324C478-D661-4D99-B390-B4476D37983B Q36998357-873BF6B9-2AA1-42F4-A215-7678318E2708 Q37555785-93873198-A84D-4C36-A097-4C6518E98CEF Q37683345-5631128B-7FE0-48CE-B0CB-F6EC2B943E91 Q37702541-0FC1CFD4-A720-48B5-A0C0-46C715DE9F9F Q38632866-084986EE-5F00-46D7-8A00-FDD093B0826F Q38712988-2BA6D1FF-B280-4055-A40F-239B467545A0 Q38725723-86E24C32-06CE-4FC6-BA6B-4185BEE7ED2F Q38761791-10842530-7E2D-43EB-96C9-BF5C32449584 Q38775472-094C6A97-DFDE-42D4-A251-77129BB630FA Q38825711-75DAAAEF-475A-453D-A9B6-6242C39B7F24 Q38848273-F6A70598-8391-4738-9232-DE0E58667145 Q38915763-F4373127-886E-4F53-A39F-C6874967D99B Q38995730-C1E8E417-F20D-4B3F-A219-C60AE87AD430 Q39125504-FA7BBEBC-3EE8-407C-9E24-C6C24A9101B5 Q39298325-89431404-AB80-4709-B448-BBA7BA46D0EE Q40377290-8561179E-F8C8-4DE8-8F01-6D7B4A0353A9 Q41576528-429B5122-17F6-4AA2-ADFB-BA2CC7DC582B Q42239094-1276BA90-A350-47BE-A8F6-087B9A68F8D6 Q44993985-225A9DCB-6081-4CF1-A36F-5C2CEFBB5CC0 Q45849227-7555CBE8-62CD-4645-A7F5-5CFF5B78CB81 Q45966435-28B93A52-FF76-4A70-A8C2-5D6A1E6D3DC8 Q47113293-52EE8D9F-8AAF-46CD-9BC2-3514CAB2A002

P2860

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

http://www.wikidata.org/entity/Q35163764

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

JAK-STAT pathway activation in ...... nesis and therapeutic response

@ast

JAK-STAT pathway activation in ...... nesis and therapeutic response

@en

type

label

JAK-STAT pathway activation in ...... nesis and therapeutic response

@ast

JAK-STAT pathway activation in ...... nesis and therapeutic response

@en

prefLabel

JAK-STAT pathway activation in ...... nesis and therapeutic response

@ast

JAK-STAT pathway activation in ...... nesis and therapeutic response

@en

P1433

Q35163764-6628881F-792C-4D86-84E5-820F29D98289

P1476

Q35163764-CA280C9C-0D1B-4B52-AEE1-A432278A4E27

P2093

Q35163764-0030C6ED-53B0-4BEE-B904-172E2C40892C

Q35163764-09CC2FB9-5C14-4699-A984-70B35CC66F69

Q35163764-1ACBD3F2-25A4-42D1-B526-143C768B53DA

Q35163764-1BEB4D62-5B05-46DC-82CF-E5AD3A86F5C4

Q35163764-26DCAA25-BEB1-414D-949E-1F58C3C27D7B

Q35163764-27FD04FA-288E-422E-BBD8-E0E7920597CD

Q35163764-2B44D3E0-6493-45EA-8619-7ED3767945BF

Q35163764-342BC063-0983-4985-B5A1-A1A8DCA34940

Q35163764-41444B54-EBCA-4283-B4C4-41901BE3E279

Q35163764-55E374AE-536D-4BAF-BFF2-A06A0F6D42DE

P2860

Q35163764-03DEB00B-2827-4819-BDDB-B426B3DFEEB1

Q35163764-05D6A68E-C52E-496D-B40E-93619AEC1BDE

Q35163764-15AE5EE8-FD7E-4B8A-92FF-794EC4099A73

Q35163764-1C5B760F-3823-48A2-B3E6-7441A14471E5

Q35163764-23B620E6-D31B-4096-B538-A0D2B1BB48AF

Q35163764-2AA8E05C-E15E-4435-95AF-08E46E1A7B2E

Q35163764-3399CBC3-2B96-42DF-BBCC-BE21507995EE

Q35163764-34D9C5C2-B212-4B91-9870-4AC67A7118E8

Q35163764-45FBBB75-6A7E-439E-BBF9-6C0C6AC42760

Q35163764-4814BB6D-1346-402A-A790-350417F5567F

P304

Q35163764-043193A9-D340-4CE0-BD8F-6329F4E9400D

P31

Q35163764-8D7E2A4E-D44D-451C-895D-4A87A9AB8393

P356

Q35163764-BF7567C6-07AB-4298-BB57-3DD6917F3129

P433

Q35163764-7D889765-36A4-4600-B6D2-07BB32F36ACF

P478

Q35163764-17E080E1-9863-4D0B-A0AF-BE7CA065BE47

P50

Q35163764-7B32AF1E-411A-440F-ABBF-6431104932AA

P577

Q35163764-5DA7E290-A781-4727-9C49-E3E5F8121071

P5875

Q35163764-0B0B2BC9-5CEE-46B3-9837-92B5A8F88178

P698

Q35163764-304FC8E1-D02E-4ABD-92D8-7C8C09818348

P932

Q35163764-F60C5B8C-EA50-41A6-B4D8-815B6E72369E

P356

2159-8290.CD-14-0736

P1433

Cancer Discovery

P1476

JAK-STAT pathway activation in ...... nesis and therapeutic response

@en

P2093

Anna Sophia McKenney

http://www.w3.org/2001/XMLSchema#string

Efthymia Papalexi

http://www.w3.org/2001/XMLSchema#string

Franziska Michor

http://www.w3.org/2001/XMLSchema#string

Jacqueline Bromberg

http://www.w3.org/2001/XMLSchema#string

Jonathan J Chen

http://www.w3.org/2001/XMLSchema#string

Jordan S Fridman

http://www.w3.org/2001/XMLSchema#string

Lennart Bastian

http://www.w3.org/2001/XMLSchema#string

Maria Kleppe

http://www.w3.org/2001/XMLSchema#string

Markus Riester

http://www.w3.org/2001/XMLSchema#string

Masato Murakami

http://www.w3.org/2001/XMLSchema#string

P2860

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

STATs in cancer inflammation and immunity: a leading role for STAT3

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

New pieces of a puzzle: the current biological picture of MPN.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

P304

316-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-14-0736

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Julie Teruya-Feldstein

P577

2015-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270653949

http://www.w3.org/2001/XMLSchema#string

P698

25572172

http://www.w3.org/2001/XMLSchema#string

P932

4355105

http://www.w3.org/2001/XMLSchema#string